Druggable genome-wide Mendelian randomization identifies therapeutic targets for metabolic dysfunction-associated steatotic liver disease

Druggable genome-wide Mendelian randomization identifies therapeutic targets for metabolic dysfunction-associated steatotic liver disease

Abstract Background Metabolic dysfunction-associated steatotic liver disease (MASLD) affects > 25% of the global population, potentially leading to severe hepatic and extrahepatic complications, including metabolic dysfunction-associated steatohepatitis. Given that the pathophysiology of MASLD is...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaohui Ma, Li Ding, Shuo Li, Yu Fan, Xin Wang, Yitong Han, Hengjie Yuan, Longhao Sun, Qing He, Ming Liu
Format: Article
Language:English
Published: BMC 2025-03-01
Series:Lipids in Health and Disease
Subjects:
CD33
Mendelian randomization analysis
MFGE8
Non-alcoholic fatty liver disease
Nonalcoholic steatohepatitis
Online Access:https://doi.org/10.1186/s12944-025-02515-8
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items